Researchers found that patients who achieved the greatest reductions in body weight after starting GLP-1-based medications had substantially lower risks of conditions including obstructive sleep apnea, chronic kidney disease, osteoarthritis, and heart failure
They also presented data suggesting the presence of putative synaptic markers in GLP-1 and enterochromaffin cells 39,58,59 , as well as viral tracing indicating synaptic-like connections with a small number of vagal afferents 38,59
Extensive phase 3 trials on semaglutide use in T2D patients showed significant reductions in blood HbA1c and fasting plasma glucose (FPG) levels within just 12 weeks of once-weekly, subcutaneously [5]
LDL, lowdensity lipoprotein
J., Smith, B., Ward, R
If you have questions about the requirements of your insurance plan, call the number on the back of your member ID card